Economic implications of SARS to China and the rest of Asia
Testimony before the
U.S.-China Economic and Security Review Commission
June 5, 2003
Dong Tao, Ph. D.
Chief regional economist for Non-Japan Asia
Credit Suisse First Boston
Six weeks after Beijing dismissed two senior officials and moved from denial to aggressive measures to tackle the SARS outbreak, the number of daily new infections has fallen sharply (no infections were reported on June 2). There may be new setbacks in the battle against SARS and rural infection remains a worry, but signs of stabilisation have emerged. Meanwhile, we now have better clarity vis-à-vis potential economic losses.
1) Consumption fell more but also rebounded quicker than we first thought. Air travel slumped 80% yoy, while rail travel dropped 60% during the May Labour Day holidays the busiest travel season outside of the Chinese New Year. We project nationwide spending fell by about 20% yoy due to reduced spending and travel cancellations, with Beijing plummeting 70% during that period. However, the consumer panic appears to have been short lived. By mid-May, sales had recovered by 90% in cities such as Shanghai, while a visible improvement in sentiment has been witnessed in Beijing as well. The consumer behaviour pattern so far is consistent with that seen in Hong Kong; thus, we expect consumers to more or less return to their normal lives in the coming weeks, barring a major set back in the control of SARS.
2) Exporters are estimated to have lost about 10-15% of orders due to SARS, but weak global demand is an even bigger threat, in our view. We have observed that some export orders were diverted to Turkey, India, Mexico and some Southeast Asian countries, as travel restrictions and fear of production interruption undermined buyers confidence these factors should show up in Q3 trade statistics. Still, if SARS is contained by the end of Q2, China will not miss the other two major order seasons of the year July and September. Besides SARS, weak global demand is also unsettling. Export growth is still expected to slip from 33.4% yoy in the first four months of this year to single digits in Q3. Production interruption does not seem to have been a major hindrance so far.
3) FDI will be affected, but Chinas fundamentals should stay mostly intact. We have spoken with some managers of major joint ventures in China, all of whom said that the epidemic would not affect their long-term strategies in China. Still, two types of investors may hold back their investment new comers who are easily affected by the western press coverage of SARS and those with very high exposure in China who need to diversify risk. Further, travel restrictions will delay the bulk of FDI into next year. We see a US$3bn loss in FDI this year and US$4-6bn next year, compared to the US$52bn figure recorded in China in 2002.
4) Fiscal stimulus to kick in H2. The government has set aside RMB8bn for disease prevention and offered tax breaks to badly hit industries, but also refrained from diluting its focus away from the SARS battle by not concentrating on stimulus measures too early. We think the size of the stimulus could reach RMB50bn or more through SARS bonds in H2. RMB50bn would represent 0.5% of GDP (the current fiscal deficit GDP ratio stands at 6%).
By all means, the repercussions from SARS to the Chinese economy are enormous, and we project 5% yoy growth for Q2. 5% growth would be considered high by US standards, but it is almost half the 9.9% growth recorded in Q1. What is clearer to us now is that most of the shock to domestic consumption is likely to be a Q2 phenomenon. We have lowered our 2003 growth forecast from 8% yoy before the SARS outbreak to 6.9%, but think that other (worse) scenarios now look unlikely to happen.
It is probably premature to claim victory over the SARS outbreak in China, but bringing the virus under control (i.e., it no longer appears in headline news) by the end of Q2 looks increasingly more realistic. More importantly, consumer confidence seems to be recovering quickly after the initial shock. There are three connected but to some extent separate curves linked to SARS: the medical curve, the economic curve and the sentiment curve. The medical curve relates to the infection and outbreak and shows some signs of stability, but the risk of a relapse after the summer must not be ruled out. But this issue is beyond my knowledge. The economic curve refers to the impacts on consumption, investment, trade and FDI. We think consumption dips first, but also recovers first. Trade will see a delayed effect in Q3, while the impact on FDI may show up even later. Our reading is that while the adverse repercussions on trade and FDI will occur later, most of the economic damages will be contained in Q2 through consumption. The third curve is the sentiment curve, which relates to consumer confidence and investor confidence. Consumer confidence deteriorated sharply but is now back on track to recovery. A repeat of the consumer panic seen in late April and early May is unlikely even if another outbreak does occur after the summer. Spending will resume as long as SARS does not dominate the headline news on a daily basis, even if there continues to be new cases in rural areas. The same can be said for equity investment sentiment, as buying opportunities remain the main objective, despite new infections. Share prices of most Hong Kong listed Chinese stocks have moved back to their pre-SARS levels.
The SARS outbreak could have the following long-term implications:
Implications to the rest of Asia: The SARS outbreak has been largely brought under control throughout Asia, though China and Taiwan (and Toronto) are still on the WHOs travel advisory list. I would like to make the following assessment: